title: Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease.
abstract: There is little information on the dynamics of BDNF in the CSF in the continuum between healthy aging, MCI and AD. We included 128 older adults (77 with amnestic MCI, 26 with AD and 25 healthy controls). CSF BDNF level was measured by ELISA assay, and AD biomarkers (Aβ42, T-Tau and P-Tau181) were measured using a Luminex xMAP assay. CSF BDNF levels were significantly reduced in AD subjects compared to MCI and healthy controls (p = 0.009). Logistic regression models showed that lower CSF BDNF levels (p = 0.008), lower CSF Aβ42 (p = 0.005) and lower MMSE scores (p = 0.007) are significantly associated with progression from MCI to AD. The present study adds strong evidence of the involvement of BDNF in the pathophysiology of neurodegenerative changes in AD. Interventions aiming to restore central neurotrophic support may represent future therapeutic targets to prevent or delay the progression from MCI to AD.
authors.affiliation: Laboratory of Neuroscience - LIM 27, Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Rua Dr. Ovidio Pires de Campos 785, 3th Floor, São Paulo, SP, CEP 05403-010, Brazil, forlenza@usp.br.
authors.forename: Orestes Vicente
authors.initials: OV
authors.lastname: Forlenza
authors.forename: Breno Satler
authors.initials: BS
authors.lastname: Diniz
authors.forename: Antonio Lucio
authors.initials: AL
authors.lastname: Teixeira
authors.forename: Marcia
authors.initials: M
authors.lastname: Radanovic
authors.forename: Leda Leme
authors.initials: LL
authors.lastname: Talib
authors.forename: Natalia Pessoa
authors.initials: NP
authors.lastname: Rocha
authors.forename: Wagner Farid
authors.initials: WF
authors.lastname: Gattaz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D001057:Apolipoproteins E / Q000235:genetics; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor / Q000134:cerebrospinal fluid* / Q000502:physiology; D060825:Cognitive Dysfunction / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; C054369:MAPT protein, human; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; C579455:BDNF protein, human